Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Neoadjuvant Erlotinib Therapy in Stage III A(N2) NSCLC
This study is currently recruiting participants.
Study NCT00600587. Last updated on January 14, 2008.
Information provided by Guangdong Provincial People's Hospital
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma, Non-Small-Cell Lung
Additional conditions recognized in this trial
Carcinoma
More general conditions related to this trial
Lung Diseases
Lung Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
neoadjuvant erlotinib therapy
Additional drug interventions recognized in this trial
Carboplatin
Erlotinib
Gemcitabine
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Guangdong Provincial People's Hospital
Hoffmann-La Roche
Back to top of Main Content